Mitochondrial complex II mutated SDHD cell line
- Name Abey Bandara
- Institute Virginia Tech
Tool name: Mitochondrial complex II mutated SDHD cell line
Alternate names: HEK293?SDHD
Tool type: Cell Lines
Tool sub-type: Continuous
Parental cell line: HEK293
Disease: Mitochondrial disease; Complex II deficiency; Paraganglioma
Growth properties: The mutant has been shown to grow much slower than the parental cell line. The doubling time of the mutant is also significantly slower than that of the parental line.
Description: The HEK293?SDHD cell line expresses a CRISPR/Cas9 mutated nuclear encoded subunit, SDHD, of mitochondrial complex II (succinate dehydrogenase). This cell line has been shown to significantly alter the function of complex II (CII) of the mitochondrial electron transport chain and displays disruptions to SDHD that mimic clinical presentations of CII deficiency. These cells represent a powerful model of metabolic pathologies, not only for mitochondrial disease, but also for understanding the importance of CII in developing novel therapeutics. CRISPR edited HEK293 cells.
Specific disruptions in SDHD have been reported to present clinically as the following disease conditions:
-Complex II deficiency
Research area: Cancer; Drug development; Metabolism
Production details: The cell line is currently stored at Virginia Tech.
Additional notes: CRISPR edited HEK293 cells.
Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here
This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.
- For Research Use Only
- • Bandara et al. 2021. BMC Mol Cell Biol. 22(1):35. PMID: 34118887.